<DOC>
	<DOC>NCT00811850</DOC>
	<brief_summary>A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.</brief_summary>
	<brief_title>Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1. Age: 30 years or older. 2. Primary openangle glaucoma (POAG) or ocular hypertensive in at least one eye. 3. Best corrected visual acuity at least 20/40 in at least one eye. 1. History of acute angleclosure or a narrow, occludable anterior chamber angle by gonioscopy. 2. History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis). 3. History or signs of intraocular trauma. 4. Any abnormality preventing reliable applanation tonometry. 5. Current use of any ophthalmic or systemic steroid which may interfere with this investigation. 6. Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>